# Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

PMC · DOI: 10.1371/journal.pone.0136515 · PLoS ONE · 2015-08-21

## Full-text entities

- **Diseases:** Age-Related Macular Degeneration (MESH:D008268)
- **Chemicals:** Ranibizumab (MESH:D000069579)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4546425/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC4546425/full.md

---
Source: https://tomesphere.com/paper/PMC4546425